“FDA Regulatory Failures in Enforcing Limits on GLP-1 Compounding Puts Patients at Risk,” critically examines the Food and Drug Administration’s (FDA) oversight of compounded GLP-1 medications. It highlights how temporary shortages of these drugs led to a surge in unregulated “knock-offs” from compounding pharmacies, even after the shortages ended. The report details the inherent risks of compounded drugs, which lack the rigorous safety and efficacy reviews of FDA-approved alternatives, and exposes schemes like “phony personalization” and reliance on dangerous foreign ingredients used by compounders to bypass regulations. Ultimately, the text calls for stricter enforcement of existing laws and increased FDA resources to protect public health from these unchecked practices, citing historical examples of harm caused by lax compounding oversight.
